CN114432354A - Helianthus annuus Linne disk for improving atherosclerosis - Google Patents

Helianthus annuus Linne disk for improving atherosclerosis Download PDF

Info

Publication number
CN114432354A
CN114432354A CN202111174160.4A CN202111174160A CN114432354A CN 114432354 A CN114432354 A CN 114432354A CN 202111174160 A CN202111174160 A CN 202111174160A CN 114432354 A CN114432354 A CN 114432354A
Authority
CN
China
Prior art keywords
atherosclerosis
sunflower
hal
discs
sunflower discs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202111174160.4A
Other languages
Chinese (zh)
Inventor
王健兵
单士军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202111174160.4A priority Critical patent/CN114432354A/en
Publication of CN114432354A publication Critical patent/CN114432354A/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The study aims to discuss the anti-atherosclerosis effect of sunflower discs and the related mechanism thereof. High fat diet for 24 weeks resulted in a C57BL background deficiency of apolipoprotein E (Apoe)‑/‑) Severe atherosclerosis, H, throughout the aorta in mice&E and oil red O staining showed severe plaques in the aortic intima, reducing the extent of high fat diet-induced atherosclerotic lesions through sunflower disc intervention. The data show that HAL reduces atherosclerosis by modulating lipid, inhibiting oxidative stress, modulating gut flora, decreasing gut permeability, and inhibiting inflammatory response. The research finds that the sunflower discs reduce the inflammatory reaction of atherosclerosis by regulating the intestinal flora and reducing the intestinal permeability. Our findings provide new insights into the role and mechanism of the anti-atherosclerotic potential of sunflower discs.

Description

Helianthus annuus disk for improving atherosclerosis
Technical Field
The invention relates to a natural oral medicament for preventing and treating atherosclerosis. The study aims to discuss the anti-atherosclerosis effect of sunflower discs and the related mechanism thereof. High fat diet for 24 weeks resulted in a C57BL background deficiency of apolipoprotein E (Apoe)-/-) Severe atherosclerosis, H, throughout the aorta in mice&E and oil red O staining showed severe plaques in the aortic intima, reducing the extent of high fat diet-induced atherosclerotic lesions through sunflower disc intervention. The data show that HAL reduces atherosclerosis by modulating lipid, inhibiting oxidative stress, modulating gut flora, decreasing gut permeability, and inhibiting inflammatory response. The research finds that the sunflower discs reduce the inflammatory reaction of atherosclerosis by regulating the intestinal flora and reducing the intestinal permeability. Our findings provide new insights into the role and mechanism of the anti-atherosclerotic potential of sunflower discs.
Background
Atherosclerosis (AS) is a lipid-driven inflammatory disease of the arterial wall and is the underlying cause of most cardiovascular diseases. One third of the worldwide deaths are caused by cardiovascular disease and are a huge economic burden. AS is the leading cause of cardiovascular disease-related morbidity and mortality, especially in the elderly population. Cardiovascular diseases are a major public health problem in China, and the burden is increasing sharply. Although primary and secondary prevention strategies significantly reduce the incidence of CVD, they are still a major cause of morbidity and mortality. Therefore, finding an effective treatment is crucial. At present, the market is lack of the AS treatment medicine which is reliable, safe and effective.
The most important pathogenic factor of AS is apolipoprotein B-containing low density lipoprotein cholesterol (LDL-C), and there is a clear causal relationship between LDL-C and cardiovascular disease. In addition to dyslipidemia, macrophages play a key role in AS, AS they are the primary cells that invade atherosclerotic lesions and form lipid-containing foam cells. These foam cells initiate the inflammatory cascade by releasing cytokines that accelerate lipoprotein retention and promote vascular inflammation. In early and middle stages of AS, including endothelial cell dysfunction, secretion of chemokines and cytokines, such AS Interleukin (IL) -1 β, IL-6, Tumor Necrosis Factor (TNF) - α, intercellular adhesion factor-1 (ICAM-1) and vascular cell adhesion factor-1 (VCAM-1) overexpression. While immune cells such as T lymphocytes, dendritic cells, and macrophages aggregate into plaques, migration and proliferation of Vascular Smooth Muscle Cells (VSMCs) into the plaques further exacerbates the inflammatory response. At the same time, VSMCs release a number of oxidation products, inactivating the vascular protective molecule Nitric Oxide (NO), leading to the development of endothelial dysfunction. Therefore, inhibition of inflammatory responses and oxidative stress may be critical for the treatment of early and intermediate AS.
In addition, there is increasing evidence that the gut microbiota is closely associated with the progression of atherosclerotic cardiovascular disease. Data show that the relationship between the intestinal microbiota and CVD in patients with coronary heart disease, a higher firmicutes to Bacteroides (F-B) ratio, a lower Bacteroides level, and a higher lactic acid bacteria level. Especially undigested dietary fiber, alters the microbial ecosystem of the gut and its composition, as the gut microbiota uses dietary fiber as a primary source of energy. The results of several human studies showed lower F-B ratios and higher bacteroidetes levels in humans on a high fiber diet. The results of large epidemiological studies have consistently supported the view that intake of dietary fiber can prevent AS.
Therefore, new therapeutic approaches should be based on reducing inflammation and oxidative stress early in the development of arterial plaque, eventually preventing the progression of the lesion to severe stenosis. At present, the medicines for improving atherosclerosis mainly comprise statin medicines and fibrate medicines, and the preventive medicines are blank. The long-term oral administration of statins and fibrates may have serious adverse effects including elevated liver enzymes, rhabdomyolysis, etc. Primary prevention of AS is of great concern once it occurs is essentially irreversible. At present, various AS-resistant health care products exist in the market, which are alleged to contain multiple active ingredients or plant extracts and the like, but the action mechanisms of the AS-resistant health care products are rejected or are not clear or effective at all, most AS-preventing products have the effects of regulating blood fat or promoting blood circulation to remove blood stasis rather than really resisting endothelial inflammation and oxidative stress, and therefore the conventional AS-resistant health care products cannot achieve the expected effect. Sunflower (A)Helianthus Annuus L.,HAL) contains flavonoids and polysaccharides as main ingredients, and may have antiinflammatory effect or antioxidant effect. Sunflower discs, AS a traditional Chinese herbal medicine, are mainly used for treating hypertension in the aspect of cardiovascular diseases, are not used for preventing and treating AS, and belong to the blank in the field. Therefore, the objective of this study was to observe whether sunflower discs have anti-AS effects and to investigate their possible mechanism of action.
Disclosure of Invention
The invention aims to clarify the function and related mechanism of sunflower discs in improving atherosclerosis.
Figure RE-92128DEST_PATH_IMAGE001
The research shows that the sunflower discs can reduce high fat diet inductionFormation of atherosclerotic plaques;
Figure RE-581187DEST_PATH_IMAGE002
the sunflower head can reduce the contents of serum LDL-C and Triglyceride (TG), increase high density lipoprotein (HDL-C) and reduce the ratio of LDL-C/HDL-C, thereby improving dyslipidemia;
Figure RE-205548DEST_PATH_IMAGE003
the sunflower discs can obviously reduce the concentration of serum Malondialdehyde (MDA), obviously improve the concentrations of superoxide dismutase (SOD), NO and glutathione peroxidase (GSH-Px), and effectively reduce endothelial cell damage caused by oxidative stress;
Figure RE-648643DEST_PATH_IMAGE004
the sunflower discs can obviously reduce the expression of serum IL-1 beta, IL-6, TNF-alpha and other inflammatory factors and reduce vascular endothelial inflammation;
the sunflower heads increase the relative abundance of bacteroidetes, reduce the relative abundance of firmicutes and obviously increase the intestinal Ackermanella (A) and (B)Akkermansiamuciniphila) And lactic acid bacteria (A), (B), (C)Lactobacillus) Abundance, and significantly reduced unidentified enterobacteriaceae: (unidentified_Enterobateriaceae) Sphingomonas(s) (ii) SSphingomonas) And Methylobacterium (meth) (meth)Methylobacterium) The results show that the sunflower extract can regulate the intestinal microbial composition of mice, increase the abundance of probiotics and reduce the abundance of harmful bacteria;
sixthly, the sunflower disc raises the level of colon occluding protein (occludin) and zon-1 (ZO-1), reduces the intestinal permeability and reduces the inflammatory mediator from entering the blood.
The technical scheme adopted by the invention
The invention is designed for animal experiments. This study will lack apolipoprotein E (Apoe) in the C57BL background-/-) 30 female mice of 8 weeks of age were randomly divided intoAnd (3) groups. The control group (control) was fed normal diet, the model group (model) was given High Fat Diet (HFD), and the HAL group was given HFD doped with 5% HAL powder. After 24 weeks of feeding, by H&E and oil red O staining the aortic plaques were analyzed. Detecting serum lipid index, and determining activity of MDA, SOD, NO and GSH-Px in aorta. ELISA method detects IL-1 beta, IL-6, TNF-alpha concentration in serum, RT-qPCR method detects IL-1 beta, IL-6, TNF-alpha mRNA expression level in aorta, 16S rRNA method detects intestinal flora composition, immunohistochemical method is adopted to determine colon occludin and ZO-1 level.
Obtaining sunflower discs: the sunflower flower disc is prepared by crushing a flower disc, from which sunflower seeds are removed, after sunflower growing in saline-alkali soil is mature, and has the main nutritional ingredients: a mixture of neutral sugars (such as d-xylan) (59.3%), alpha-cellulose (52%), pectin (27.5%) and lignin (12.3%). Separating the sunflower disc extract by chromatography to obtain 11 diterpene compounds. Their structure is elucidated by spectroscopic data analysis. They include: -epoxy-17-al-19-oic acid, ent-kaurane-2-16-diol, ent-kaurane-15-16 ent-kaurane-16 β -ol, phenylloran-16 β -ol, ent-tisan-16-ol, grandifloric aicd, angeloylgrandifloric aicd, ent-kaurane-16-en-19-oic aicd, ent-kaurane-17-hydroxy-15-en-19-oic aicd, ent-kaurane-16 β -17-dihydroxy-19-oic aicd and ciliaric aicd.
Prevention and treatment effect of sunflower discs on atherosclerosis
The results of the study suggest that after 24 weeks of feeding, lipid plaque formation was found to be visible in the whole aorta of the model group mice (fig. 1). To assess the effect of sunflower discs on atherosclerotic plaques, we performed H & E staining (fig. 1.1) and ORO staining (fig. 1.2). We observed that high fat diet significantly increased the percentage of atherosclerotic plaques, while H & E positive and ORO positive decreased significantly after sunflower disc treatment, indicating a decrease in atherosclerotic plaque formation.
The results of the serum lipid analysis are shown in table 1. (iii) the serum total cholesterol, triglyceride, low density lipoprotein and LDL-C/HDL-C in the model group are found to be obviously increased compared with the control group: (P<0.01). Serum Total biliary fixation in HAL group compared to model groupSignificant decreases in alcohol, triglycerides, low density lipoproteins, and LDL-C/HDL-C (TG, TC:P<0.05, the restP<0.01). (Table 1)
TABLE 1 comparison of blood lipids for each group
Figure RE-42059DEST_PATH_IMAGE005
The concentrations of MDA, SOD, NO, GSH-Px in aortic tissue were determined and are shown in Table 2. Compared with the control group, the concentration of the pro-oxidation factor MDA of the model group is obviously increased (P<0.05), the concentrations of antioxidant factors SOD, NO and GSH-Px are obviously reduced (P<0.01). HAL significantly reduced serum MDA concentrations compared to model groups (P<0.05), the concentrations of SOD, NO and GSH-Px were significantly increased (GSH-Px: P<0.05, the restP<0.01). (Table 2)
TABLE 2 comparison of the levels of oxidized cytokines in aortic tissues for each group
Figure RE-401757DEST_PATH_IMAGE006
We found that the contents of IL-1, IL-6 and TNF-alpha in serum are obviously increased in the model group compared with the control group (see table 3) (the concentrations of proinflammatory factors IL-1 beta, IL-6 and TNF-alpha in the model group are obviously increased: (P<0.05). HAL significantly reduced serum IL-1 β levels compared to model groups (P<0.01), significantly reduce the content of IL-6 and TNF-alpha in serum (P<0.05). The mRNA expression levels of IL-1 beta, IL-6 and TNF-alpha in aorta were determined by RT-qPCR with primers as shown in Table 4. Expression of IL-1 β, IL-6, TNF-a in the aorta is shown in FIG. 2. Compared with the control group, the expression of IL-1 beta, IL-6 and TNF-TNF-in the model group is obviously increased (P<0.01). HAL significantly reduced its expression concentration compared to the model group (P<0.01). (FIG. 3 and tables 3 and 4)
TABLE 3 comparison of serum inflammatory cytokine levels in each group
Figure RE-46709DEST_PATH_IMAGE007
TABLE 4 mouse target Gene primer sequences
Figure RE-556144DEST_PATH_IMAGE008
Changes in the intestinal microbiota of AS model mice after HAL treatment were studied using high throughput sequencing of 16S rRNA. We obtained 77328 available reads and 1576 Operable Taxa (OTUs) from 18 samples. The Shannon diversity index of the model group was higher than that of the control and HAL groups (fig. 3.1). Venn plot analysis showed a total of 824 OTUs, 938 both in the control and model groups, 882 in the control and HAL groups, and 970 in the model and HAL groups (FIG. 3.2). The primary coordinate analysis (PCoA) showed that the intestinal flora of the model group and the HAL group were statistically different from the control group (fig. 3.3). Consistent with this result, phylogenetic trees showed significant differences between groups (fig. 3.4), and the species of intestinal flora and their relative abundance were further investigated. At the phylum level, all samples had 10 phyla, the most abundant of which was Bacteroides: (A) ((B))Bacteroidetes) And Thelluria firma: (Firmicutes) (FIG. 3.4). Of sets of modelsFirmicutesThe relative abundance is obviously higher than that of the control group,Bacteroidetesis significantly lower than the control group. HAL is increased compared with model groupBacteroidetesRelative abundance of, reduceFirmicutesRelative abundance of (c) (fig. 3.4). At the genus level, model groupAkkermansia muciniphila(FIG. 3.5a) andLactobacillusrelative abundance (fig. 3.5b) no difference compared to control group: (P>0.05), compared to the model group and the control group, and the HAL groupAkkermansia muciniphilaIs significantly increased (P)< 0.01),LactobacillusAlso model increases in abundance of (a) ((ii))P<0.05). Model setunidentified_ Enterobateriaceae(P<0.01, FIG. 3.5c),Sphingomonas(P<0.01, FIG. 3.5d) andMethylobacterium(P<0.05, fig. 3.5e) was higher relative abundance than the control group. HAL is significantly reduced compared to the model groupunidentified_Enterobateriaceae(P<0.01Sphingomonas(P<0.05) andMethylobacterium(P<0.05) abundance in the intestinal tract. Taken together, these results indicate that HAL can modulate the gut microbiota composition, increase probiotic abundance, and decrease harmful bacterial abundance in AS model mice. (FIG. 3)
Intestinal permeability was analyzed by immunohistochemical staining. Through detection, compared with a control group, the levels of model colon occludin (occludin, figure 4.14.3) and tight junction protein 1 (ZO-1, figure 4.24.4) are obviously reduced (P<0.01). The level of occludin and ZO-1 in HAL group was significantly increased compared with that in model group (P<0.05), suggesting that HAL may elevate colonic occludin and ZO-1 levels, decrease colonic permeability, and reduce inflammatory responses by reducing the influx of inflammatory mediators into the blood. (FIG. 4)
In conclusion, the research result shows that the sunflower discs improve atherosclerosis by regulating lipid, inhibiting vascular endothelial oxidative stress and inflammatory reaction. The research finds that the sunflower discs reduce inflammatory reaction by regulating intestinal flora and reducing intestinal permeability so as to improve atherosclerosis. One of the highlights of this study is that we have conducted more intensive mechanistic studies in animal models and have obtained consistent results.
Drawings
FIG. 1.1: h & E staining (200 ×); 1.2: ORO staining (400X).
FIG. 2.1: IL-1. beta. mRNA aortic expression; 2.2:: IL-6 mRNA aortic expression; 2.3: TNF-alpha mRNA is expressed in the aorta.
FIG. 3.1: all samples are thinned to Shannon index calculated after reading equivalent sequence; 3.2: venn plot of the number of OTUs from each group; 3.3: PCoA score; 3.4: gut flora phylogenetic clustering trees, HAL treatment altered microbial communities at the phylum level (bar graph); 3.5: the relative abundances of each bacterium Akkermansia (a), Lactobacillus (b), unidentified _ Enterobacteriaceae (c), Sphingomonas (d), Methylobacterium (e).
FIG. 4.1: occludin; 4.2: ZO-1; 4.3: quantitative analysis of Occludin; 4.4: and (4) carrying out quantitative analysis on ZO-1.

Claims (2)

1. The function of improving atherosclerosis of sunflower discs is characterized in that: the atherogenic effect of sunflower discs was shown by a reduction in high fat diet-induced aortic plaque formation.
2. The sunflower discs of claim 1 have effects in regulating lipid, relieving inflammation, resisting oxidative stress, regulating intestinal flora, and reducing intestinal permeability.
CN202111174160.4A 2021-10-09 2021-10-09 Helianthus annuus Linne disk for improving atherosclerosis Withdrawn CN114432354A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111174160.4A CN114432354A (en) 2021-10-09 2021-10-09 Helianthus annuus Linne disk for improving atherosclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111174160.4A CN114432354A (en) 2021-10-09 2021-10-09 Helianthus annuus Linne disk for improving atherosclerosis

Publications (1)

Publication Number Publication Date
CN114432354A true CN114432354A (en) 2022-05-06

Family

ID=81362525

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111174160.4A Withdrawn CN114432354A (en) 2021-10-09 2021-10-09 Helianthus annuus Linne disk for improving atherosclerosis

Country Status (1)

Country Link
CN (1) CN114432354A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129423A (en) * 2007-08-13 2008-02-27 淄博济世保健食品科技有限公司 Golden flower mallow health care oral liquid and method of preparing the same
CN112972508A (en) * 2020-04-16 2021-06-18 江苏苏中药业集团股份有限公司 Application of abelmoschus manihot extract as TRPC (TRPC ion channel inhibitor)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129423A (en) * 2007-08-13 2008-02-27 淄博济世保健食品科技有限公司 Golden flower mallow health care oral liquid and method of preparing the same
CN112972508A (en) * 2020-04-16 2021-06-18 江苏苏中药业集团股份有限公司 Application of abelmoschus manihot extract as TRPC (TRPC ion channel inhibitor)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIANBING WANG ET AL.: "Helianthus Annuus L. Alleviates High-Fat Diet Induced Atherosclerosis by Regulating Intestinal Microbiota, Inhibiting Inflammation and Restraining Oxidative Stress", <THE AMERICAN JOURNAL OF CHINESE MEDICINE> *

Similar Documents

Publication Publication Date Title
Bian et al. Kaempferol reduces obesity, prevents intestinal inflammation, and modulates gut microbiota in high-fat diet mice
Ran et al. Sea buckthorn (Hippophae rhamnoides L.) fermentation liquid protects against alcoholic liver disease linked to regulation of liver metabolome and the abundance of gut microbiota
Hlivak et al. One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels
TW200944215A (en) Lactobacillus isolates having anti-inflammatory activities and uses of the same
Wang et al. Phenolics from noni (Morinda citrifolia L.) fruit alleviate obesity in high fat diet-fed mice via modulating the gut microbiota and mitigating intestinal damage
KR102397916B1 (en) A novel anaerobic microbe isolated from human milk and method of preventing or treating metabolic disease using thereof
CN106962933B (en) Application of nymphaea hybrid extract and composition thereof in preventing obesity and improving intestinal flora
Aspiras et al. Hepatoprotective effect of Fermented Water Kefir on Sprague-Dawley rats (Rattus norvegicus) induced with sublethal dose of Acetaminophen
KR20130033591A (en) Fermented soybean
Yi et al. Effects of Lactobacillus fermentum CQPC04 on lipid reduction in C57BL/6J mice
WO2023066973A1 (en) Probiotic strains for reducing blood cholesterol and/or treating dyslipidemia, and methods for using and producing the same
Ma et al. The novel intervention effect of cold green tea beverage on high-fat diet induced obesity in mice
US8455017B2 (en) Active substance for improving hyperlipidemia and hypercholesterolemia
Hua et al. Healthy regulation of Tibetan Brassica rapa L. Polysaccharides on alleviating hyperlipidemia: a rodent study
Wang et al. Development of a polyphenol‐enriched whole kiwifruit dietary supplement and its potential in ameliorating hyperlipidemia
Werdiningsih Effects of red pitaya (Hylocereus polyrhizus) on lipid profile of male white rats (Rattus norvegicus) receiving high fat diet
CN117866798A (en) Lactobacillus fermentum GLF-217 and its use in ulcerative colitis, hyperlipidemia and reduction of organ damage
CN114432354A (en) Helianthus annuus Linne disk for improving atherosclerosis
CN110074392A (en) A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof
CN110801446A (en) Application of nitrilamine in preparation of colitis treatment medicine
CN110496192A (en) A kind of natural medicinal formulations for preventing and treating atherosclerosis by adjusting intestinal flora balance
CN115463159A (en) Application of Acermanium and Acermanium postbiotic in preparation of medicine or health-care product for preventing or treating hepatic steatosis
KR102390048B1 (en) Composition for preventing or treating alcoholic fatty liver disease comprising fermented pyrus ussuriensis extract as an active ingredient
CN114532503B (en) Red apple and cherry plum composition and application thereof in reducing blood fat
JP7303372B2 (en) COMPOSITION FOR PREVENTING, IMPROVING OR TREATMENT OF LIVER INJURY AND METHOD FOR PREVENTING, IMPROVING OR TREATMENT OF LIVER INJURY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220506